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Abstract
Many major technical developments have occurred during the last decades in 
radiotherapy: our efficacy has improved with less toxicity. Nowadays, it allows us 
to challenge the role of surgery as a local modality for lung cancer both for early, 
advanced and even metastatic disease. In the present paper, we will mainly discuss 
the role of SBRT for stage I lung cancer, the place of conventional radiotherapy for 
stage III and we will review the current treatment of small cell lung cancer from a 
radiation oncologist perspective.
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1. Introduction
Radiation oncology is an important player in the treatment of lung cancer 
either alone taking advantage of the new technological developments (stereotactic 
radiotherapy, intensity modulated radiotherapy, image guide radiotherapy) or with 
surgery and systemic treatment (chemotherapy, immunotherapy, targeted drugs). 
To-day, radiotherapy may even challenge surgery as the loco-regional treatment 
both for stage I and III non-small cell lung cancer (NSCLC) and is the local treat-
ment for small cell lung cancer (SCLC). In the present chapter, we will discuss those 
different clinical situations and presenting the current knowledge.
2. Stage I lung cancer: radiotherapy as an alternative to surgery
2.1 Stereotactic radiotherapy for early stage lung cancer (SBRT)
Surgery is the treatment of reference for early stage lung cancer and a lobectomy 
or an anatomical segmentectomy in selected cases coupled with a lymph node dis-
section is the preferred approach [1]. For early stages, surgery is generally technically 
less complex and associated with less toxicity and mortality than for more advanced 
stages. Still, some patients cannot undergo surgery due to medical comorbidities. 
In the past, conventional (long course) radiotherapy or even no treatment was 
often proposed to those patients; the outcome was very poor: in a review, the 2-year 
survival rates range from 22 to 72% and the 5-year survival rates from 0 to 42% [2].
In early 1990’s, a new radiotherapy technique emerged in Europe and Japan, 
built on the experience with intracranial stereotactic treatments, called stereotactic 
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hypofractionated radiotherapy, stereotactic irradiation (STI), or extracranial stereo-
tactic radioablation (ESR), and now more commonly referred to Stereotactic Body 
Radiation Therapy (SBRT) or Stereotactic Ablative Radiotherapy (SABR) [3, 4]. This is 
a novel form of high-precision, image-guided radiotherapy and aims to deliver higher 
radiation doses in a reduced number of fractions resulting in a higher Biologically 
Effective Dose (BED) than “conventional RT”, i.e. a higher biological impact for a given 
physical dose. This approach treats only the tumour without any coverage of the hilar 
or mediastinal lymph nodes.
Several retrospective studies observed encouraging results for early stage lung 
cancers and in 2006, the results of a prospective phase II trial testing SBRT for 
inoperable patients was published by Timmerman et al.: encouraging oncological  
outcomes were confirmed with 60 Gy or 66 Gy delivered in 3 fractions for T1 
or T2 tumours [5–7]. However, the trial also showed an 11-fold increase in high 
grade toxicity, including even death. This was associated with the treatment 
of perihilar/centrally located tumours, those in a region close to the proximal 
bronchial tree that was later referred to as the “no-fly-zone”.
In 2010, the phase II trial NRG Oncology Radiation Therapy Oncology Group 
(RTOG) 0236 reported a 97.6% 3-year local control (LC) rate (95% CI 84.3–99.7) 
for a cohort of 55 patients with a T1–T2N0M0 peripheral lesion (tumour diameter 
less than 5 cm) treated with 3 fractions of 18 Gy [8]. Toxicity was limited with 
2 grade 4 events and no grade 5. This trial updated results was reported in 2018 
with a median follow-up of 48 months: recurrences at the primary site were rare at 
5 years (7.3%) but the 5-year disease-free survival and overall survival (OS) rates 
were respectively 25.5% and 40.0% [9]. If SBRT is very effective to treat a specific 
lesion, occult spread may already occur and impact prognosis as well as intercur-
rent death related to the patient comorbidity. Data from larger cohorts and many 
other phase 2 trials also confirmed that SBRT is an effective and safe approach for 
inoperable patients but some studies also included medically operable patient who 
had refused a surgery [10–13]. The latter group showed a better outcome due to less 
intercurrent death with even long term survival data close to the surgical series [14]. 
Furthermore, in the US National Cancer Data Base, Nanda et al. reported better 
survival for elderly patients (70 years or older) treated with SBRT than no treat-
ment and this was still valid regardless of patient age [15]. Last but not least, SBRT 
was compared to conventional RT in two randomised trials: a better outcome was 
observed with less toxicity and was more convenient for the patients by reducing 
the travels to the radiotherapy department [16, 17].
2.2 Central tumours
Central tumours represent a challenge after the toxicity reported by the RTOG 
phase II trial [7]. Different groups have tried to identify treatment possibilities for 
these patients, mainly with different dose-fractionation schemes or with lower 
doses to the periphery of the planning target volume (PTV) than 3 fractions of 
20 Gy [18–21]. With more data available from many centres, a distinction was 
necessary within the central tumours located within the no-fly-zone: the distance 
to the bronchial tree and the oesophagus was crucial in determining the toxicity 
risk and leading to the definition of ultra-central tumours (UC): meaning the PTV 
overlaps the proximal bronchial tree or the oesophagus [21, 22]. A systematic review 
published in 2019 reported on the results of nine trials with at least 5 UC tumours, 
for a total of 291 patients but all studies have a slightly different definition for an 
UC [23]. SBRT treatments delivered a BED (for a α/β ratio of 10 Gy, BED10 Gy) of 
67.2 Gy (48 Gy in 12 fractions) to 112.5 Gy (50 Gy in 4 fractions). Grade 3 toxicity or 
more ranged from 0% in two smaller-sized trials up to 55.5% at 2 years including 10 
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deaths in a cohort of 47 patients. In this particular trial there was no dose limit to the 
trachea and main bronchi and there was a great difference between the prescribed 
dose and the maximum dose delivered. In total, 8 studies reported grade 5 complica-
tions, mostly due to haemorrhage (15 of 22 cases). All studies reporting statistical 
comparisons of outcomes did not find differences in OS (6 studies) or LC (4 studies) 
between central and ultra-central tumours. Furthermore, six trials described a 
statistical comparison of toxicity rates without any significant difference.
The question of the best radiation management for non-peripheral tumours 
is currently still open and being examined by the LungTech and SUNSET trials, 
respectively investigating central and ultra-central localizations [24, 25]. In cur-
rent clinical practice, SBRT is commonly performed for central tumours or isolated 
mediastinal lymph nodes at lower doses than peripheral tumours. In Onishi experi-
ence, a BED10 Gy > 100 Gy was decisive to obtain a high local control and survival 
with SBRT [6]. For (ultra-)central tumours, this cannot always be achieved, but at 
the same time, dose constraints for central airways and oesophagus can be observed 
to avoid severe toxicity but at the price of a lower efficacy.
2.3 SBRT vs. surgery
Since the early 2010’s, SBRT is accepted as a standard treatment for patients 
medically inoperable or refusing surgery. As comorbidities can also prevent a safe 
biopsy, SBRT is now accepted for the management of lesions highly suspicious of 
lung cancer without necessary a histological confirmation. SBRT has a favourable 
toxicity profile and a good local efficacy and SBRT may challenge surgery. Survival 
outcomes of SBRT could seem somewhat poor when compared to surgical series. 
However, most patients treated with SBRT present severe comorbidities or were 
older and such a direct comparison of survival is not appropriate. These comor-
bidities could dramatically impact prognosis by influencing further treatments, 
non-cancer related survival…
Several studies performed propensity score matching to compare surgical and 
SBRT patients’ outcomes with controversial results. A meta-analysis of propensity 
score matched studies was published in 2019 including 15 studies [26]. The results 
seemed to confirm a better 3-year OS after surgery but these results were ques-
tionable as unbalance remained in the matchings, meaning that patients were not 
similar after all. When restricting the analyses to studies with comparable covari-
ates, no statistically significant difference in OS was found anymore. Selection 
biases seem inevitable in clinical practice, and so the need for randomised trials is 
generally recognised.
Several phase III trials randomised patients for SBRT or surgery and were initi-
ated by different groups. STARS (registered as NCT00840749 on ClinicalTrials.
gov), started in 2008 in the United States, aiming to identify a difference in 3-year 
OS, which required enrolment of 1030 patients over an expected period of 7 years. 
After having recruited 36 patients in 4 years, enrolment was prematurely closed. 
The ROSEL trial (NCT00687986) that started in the Netherlands, also in 2008, 
faced a similar situation as only 22 of the 900 patients planned could be enrolled.
A pooled analysis of the STARS and ROSEL cohorts was published in 2015 [27]. 
These trials were quite similar in terms of inclusion criteria and interventions, 
although central tumours were eligible in the STARS trial only (two were included). 
For the 58 patients enrolled, 31 were treated with SBRT (20 in STARS, 11 in ROSEL) 
and 27 with surgery. All surgical patients had hilar lymph node dissection and 
either dissection or sampling of several mediastinal nodal levels. Radiotherapy 
treatments for peripheral lesions were 54 Gy in three 18 Gy fractions in both trials 
but could also have been 60 Gy in five fractions in ROSEL trial (which happened 
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for 5 patients), based on the practice of treating centres. It should be noted that, as 
often the case in RT, the prescription corresponded to technically slightly different 
treatments between the two trials.
Although based on few patients, the Chang analysis showed a statistically 
significant difference in OS with estimated survival rates at 1 and 3 years of 100% 
(95% CI 100–100) and 95% (85–100) in the SBRT arm for 88% (95% CI 77–100) 
and 79% (95% CI 64–97) in the surgical group (log rank p = 0.037, HR 0.34, 95% CI 
0.017–1.19). Only seven deaths were reported: one patient in the SBRT group who 
died of cancer progression and six patients in the surgery group (three from lung 
cancer including a second primary, two from comorbidities and one from attrib-
uted to the surgical treatment). Both the STARS and ROSEL trials surgical groups 
included patient treated with the older thoracotomy technique and not the more 
actual and less morbid Video-Assisted Thoracoscopy (VATS).
To put things into perspective, a meta-analysis based on 40 SBRT studies 
(10 prospective, 30 retrospective) and 23 surgery studies (all retrospective), for 
respectively 4850 and 7071 patients, reported unadjusted 3-year OS for SBRT, 
lobectomy and sublobar resections of 56.6%, 80.7%, and 77.8%, respectively [28]. 
After adjustment for suitability for surgery (which integrates comorbidities and 
age), the estimated survival rates were higher for SBRT patients, although not sta-
tistically different, with 89% (95% CI 76–95) vs. 81% (95% CI 76–85) for lobectomy 
and 80% (95% CI 76–86) for limited lung resection. Currently, the Veteran admin-
istration is running a large phase III trial comparing surgery to SBRT (VALOUR 
trial) [29]. Interesting, the trial includes operable patients with tissue confirmation 
of NSCLC, staging with FDG-PET/CT, and biopsies of all hilar and/or mediastinal 
lymph nodes >10 mm that have a SUV >2.5. SBRT doses depend on the tumour loca-
tion: peripheral tumours will receive either 18 Gy x 3,14 Gy x 4, or 11.5 Gy x 5 frac-
tions, while central tumours will be treated with 10 Gy x 5. The surgery will be either 
a lobectomy or anatomic pulmonary resection (a segmentectomy) and mediastinal 
lymph node sampling.
If indeed new decisions regarding patients’ management cannot be made based 
on a post-hoc analysis of two very small sample trials and observational data, the 
superiority of the surgical approach might not be certain anymore and randomising 
large numbers of patients is still necessary to provide level-I evidence to answer the 
question.
The major accrual problem in these trials was attributed to the lack of equipoise 
in the physicians’ minds, or maybe to financial considerations. The two treatment 
modalities are very different, which can have strong impact on both patients and 
physicians limiting the acceptability of leaving the treatment choice to chance. 
Surgery is performed on in-patient basis. As the tumour is removed, it is easier to 
identify local recurrences. Mediastinal nodal dissection or sampling also allows 
to identify false negative of PET/CT staging and to guide the decision for an adju-
vant treatment. In many SBRT series, the mediastinal evaluation is often limited 
to the CT or the PET-CT with fewer patients having a mediastinal sampling with 
Endobronchial Ultrasonography – Transbronchial Needle Aspiration (EBUS–TBNA). 
Even though an operable patient could be safely operated for salvage in the rare cases 
of regional relapse, it is probably better to provide the most exhaustive staging pos-
sible before choosing the treatment modality.
Another issue is the extra-thoracic failure suggesting to add a systemic treat-
ment. The patients treated currently with a SBRT have often many co-morbidities 
and are not the good candidate for adjuvant chemotherapy due to the acute toxicity. 
An answer may be immunotherapy following the impressive positive results for 
more advanced stages: pembroluzimab, durvalumab and atezolumab are tested 
in different trials (KEYNOTE-867, PACIFIC-4, SWOG S1914) as an adjuvant 
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treatment or concurrently with SBRT. An important issue will be the tolerance and 
the toxicity in this elderly population.
In conclusion, SBRT is an effective treatment modality and a very acceptable 
alternative to surgery for patients at high surgical risk. For fit patients, a large scale 
randomised trial is still considered necessary to answer the question: can SBRT 
replace safely surgery?
3. Stage III non-small cell lung cancer
To-day, most fit patients with a stage III NSCLC are treated with a program 
of chemoradiotherapy favouring a concurrent approach (CRT) [30]. The results 
remain far from satisfactory in term of overall survival. This is due to distant 
metastases and loco-regional failure. Using all our technological developments 
(IMRT, image guided radiotherapy, PET-CT based planning), local failure is still a 
major challenge even after doses in excess of 60 Gy. In the recent trial conducted 
by the RTOG comparing 60 to 74 Gy, the 5 year local failure rates are 49.7% after 
60 Gy and 55.4% after 74 Gy [31]. Adding a third modality, surgery, is an appeal-
ing approach already proposed many years ago by Strauss and Sugerbacker in their 
literature review [32]. From a theoretical point of view, there is a clear synergism 
between radiotherapy and surgery: failure after radiotherapy is often observed 
in the bulk of the tumour, an area of hypoxia less sensitive to radiation while for 
surgery, local relapses occur at the margins of resection. Another approach is to 
improve the systemic treatment by adding immunotherapy.
There are several ways of combining the three modalities: induction chemo-
radiotherapy (concurrent or sequential) followed by surgery or a sequential 
approach with an induction chemotherapy followed by surgery and postoperative 
radiotherapy (PORT). The latter has the advantage to have less toxicity, the ability 
to evaluate the response to the chemotherapy especially the possible downstaging of 
mediastinal nodes allowing selecting the best candidate for surgery, the use of full 
dose of chemotherapy, to treat the possible micro metastatic spread and to have a 
full pathological evaluation. The drawback is that PORT will be less efficient due to 
the poor vascularization and the loss of lung volume especially in case of a pneumo-
nectomy. The former allows taking advantage of the radiosensitizing properties of 
many drugs to obtain a higher rate of tumour response including pathologic com-
plete response but at the price off more surgical complications and more toxicity. 
The ultimate goal of a three-modality approach is to improve survival while local 
control and progression free survival (PFS) are only surrogate endpoints.
3.1 Induction chemoradiotherapy before surgery
Many phase II trials reported a higher response rate, more downstaging and 
pathologic complete response but also more postoperative complications with CRT 
compared to chemotherapy alone. Using the National Cancer database including 
more than 11,000 patients with stage III NSCLC, the trimodality approach let to a 
better outcome with a 5-year survival around 32% [33]. In another analysis from the 
same database, 1936 patients with a T1, T2 N2 disease were treated with preopera-
tive CRT or induction chemotherapy [34]. The pathologic complete response was 
higher after CRT (14.2% vs. 4%) but with an increased perioperative mortality and 
no improvement in OS. One problem with databases even a large one is certainly 
all the possible biases of patient selections but also the difference in local medi-
cal facilities. Indeed, academic facilities were more likely to treat patient with the 
trimodality than in a community hospital [35]. This is well illustrated by a recent 
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paper including more than 83,000 patients presenting a stage III NSCLC treated 
in 1319 facilities. Those treated in a high volume centre (more than 15 patients) 
were more likely to have surgery or a trimodality and had significantly a lower risk 
of death [36]. This is one reason to look more to randomised trials to answer the 
question.
The role of surgery after a concurrent CRT compared to an exclusive CRT 
approach was tested by two trials conducted in Germany and in the US [37, 38]. 
Both trials did not observe any difference in OS but only a better local control after a 
surgical resection or a better PFS. Do we need to include radiotherapy in an induc-
tion program? The main advantage of avoiding RT is to reduce the acute toxicity 
and the surgical complications. Three randomised trials compared induction 
chemotherapy to a CRT approach for patients presenting with N2 disease initially 
considered resectable. The Swiss trial is the largest one and the most recent [39]. 
232 patients were randomised between induction chemotherapy followed 4 weeks 
later by surgery and induction chemotherapy followed by RT (44 Gy in 22 fractions 
and 3 weeks) without any chemotherapy and surgery 3 to 4 weeks later. PFS and 
OS were not found different between the two arms. A R0 resection was observed in 
91% and 81% in the arm with or without RT respectively. The pathologic complete 
responses were very similar with respectively 16 and 12%. Interestingly, no opera-
tive mortality was reported after RT. The main criticism is the use of a sequential 
approach perhaps explaining the low rate of pathological complete response. 
Recently, our Spanish colleague reported 99 patients treated with either preopera-
tive CRT or induction chemotherapy. CRT significantly increased the pathologic 
complete response rate and nodal down staging and reduced the loco-regional 
recurrence; unfortunately, this did not translate in any survival benefit [40].
PreCRT is a commonly used strategy in patients with superior sulcus tumours. 
In two phase II trials including 110 and 76 patients, a CRT delivered 45 Gy com-
bined with cisplatin, etoposide or cisplatin, vindesine, mitomycin chemotherapy. 
A N2 disease was an exclusion criterion. The 5-year survival rates were 44% and 
56%, respectively [41, 42]. Important prognostic factors were R0 resection and 
pathologic complete response. One drawback is the relatively low RT dose in case of 
no surgery or incomplete resection. Another approach is to deliver a full RT dose. 
In a Dutch series, 49 patients treated with CRT before surgery (19 patients) or as 
a definitive treatment (30 patients) [43]. 5-year survival was 33% for the three 
modalities and 18% for the definitive RT. Clearly, patients selected for the trimodal-
ity were highly selected.
3.2  Induction chemotherapy followed by surgery and postoperative 
radiotherapy
Most trials evaluating PORT were carried out in an era of old radiation technique 
and not after induction chemotherapy. The meta-analysis showed a detrimental 
effect of PORT especially for stage I and II disease [44]. Another meta-analysis 
stratified the trials according to the use of a cobalt 60 unit or a linear accelerator 
[45]. PORT carried out with a linear accelerator increased OS and local control for 
stage III disease. Many retrospective analyses from single centre or from large data 
base look at the impact of PORT for stage III: if local control was improved, the 
impact on survival led to conflicting results.
RT technique is a key factor to avoid an excessive toxicity. The radiation plans 
used in the trials included in the meta-analysis were compared to our current RT 
techniques [46]. The older technique led to poor target coverage and an excessive 
toxicity. The target coverage reached only 65% and the heart V30Gyand the lung 
V20Gywere higher with the technique used in the randomised trials. A Polish study 
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evaluated the cardio-respiratory functions in patients who did and did not receive 
modern PORT technique: they observed no increase in non-cancer radiation-
induced mortality or deterioration of lung functions [47].
Currently, another issue is the role of PORT after induction chemotherapy for 
N2 disease since local relapse is a common feature as observed in several prospective 
phase II series. The cumulative loco regional recurrence rose even to 60% in the 
Betticher trial including 75 patients treated with upfront chemotherapy followed 
by surgery [48]. Persistent N2 disease after ICT is a pejorative factor but several 
questions on PORT remain: the place of PORT according to the pathologic response 
ypN0 versus ypN2 and PORT only or with sequential or concurrent chemotherapy. 
The data were coming from retrospective studies but the results of the LungArt trial 
were just presented at the ESMO congress: this phase III trial compared mediastinal 
PORT (54 Gy in 27–30 fractions) to no PORT. Patients included had a complete 
resection with nodal exploration, proven N2 disease and neo or adjuvant chemo-
therapy. PORT was associated with a non- statistically significant 15% increase in 
DFS at 3 years but without an OS benefit [49].
3.3 Discussion
All those trials have a major problem: they were conducted many years ago and 
are not in agreement with our current practice due to technological developments in 
diagnostic procedure (MR, PET-CT), in radiotherapy and in surgery and to the new 
drugs available including target agents and immunotherapy. Clearly, those data do 
not help us to choose between a trimodality and a concurrent chemoradiotherapy as 
the results suggest similar outcome in term of survival. Furthermore, stage III is a 
very heterogeneous group of tumours and the TNM has evolved over the years with 
different stage grouping both for the T and the N components in the different UICC 
classifications. Many trials have only included N2 patients or stage IIIA while other 
also included stage IIIB.
Nevertheless, there are a few lessons we have learned. One concern using induc-
tion chemotherapy before a local treatment is the delay between its termination 
and the start of the local treatment: accelerated repopulation of cancer cells and 
tumour regrowth can occur [50]. This is even more valid when the decision to do 
the surgery is taken after the induction treatment to see the possibility of a resec-
tion with free margins. In case of no resection or incomplete resection, the patient 
may have not an optimal curative treatment as the preoperative RT dose is often too 
low to achieve a good local control. Moreover, the addition of a boost delivered after 
several weeks of RT interruption is not very effective due to tumour repopulation.
The decision between both approaches should be discuss on individual base after 
a careful patient evaluation with a full staging including PET-CT and brain MR to 
avoid a futile treatment and an evaluation of patient fitness to undergo surgery or 
even radiotherapy. Many patients have a long history of tobacco smoking and are 
suffering from many co-morbidities increasing the risk of complications or even 
not allowing a surgical resection. The decision is to be taken during a tumour board 
involving all specialties: the feasibility of a complete resection with free margins 
should be evaluated; an incomplete resection is by definition a futile thoracotomy 
and salvage treatments have limited efficacy. Another issue is the possibility to 
deliver a full course of radiotherapy with concurrent chemotherapy. This implies 
to be able to deliver doses in excess of 60 Gy or a biological equivalent dose taken 
into account the tolerance of the different organs at risk including the normal lung 
but also the heart. Finally yet importantly, an essential parameters are the local 
treatment facilities and the local clinical expertise but also the discussion with the 
patient of the pros and cons.
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3.4 Immunotherapy with anti PDL1 drugs
If immunotherapy approach was in the past not very successful especially 
the vaccination strategies; the current approach is to play on T-cell activation or 
modulation in the tumour or microenvironment using anti-PD-1/PD-L1 drugs. 
Those drugs have fully changed the pattern of care for stage IV NSCLC with marked 
improved survival. It was often consider that RT had an immunosuppressive effect. 
Nowadays, there is a body of evidence suggesting that RT may increase the immune 
response both locally and systematically [51]. RT may act through a spectrum of 
cellular and molecular alterations and through the release of tumour-associated 
antigen. There are now a lot of observations suggesting a synergistic action of RT 
with anti-immune-checkpoint blockades with anti-PD-(L)1. Experimental data 
showed an increase in the expression of PD-L1 at the surface of tumoral cells after 
RT, improving the survival [52].
An interesting observation was seen in the phase I trial with pembrolizumab in 
stage IV NSCLC: in the phase I trial Keynote-001, patients treated with radiother-
apy prior to pembrolizumab had a better survival regardless of the site irradiated 
[53]. In case of chest RT, 3 patients out of 24 developed a grade 3 lung toxicity after 
prior RT compared to one 1 out of 73 for pembroluzimab.
PACIFIC is a large scale phase III trial comparing durvalumab (an anti-PD-L1 
antibody) to a placebo as a consolidation treatment after chemoradiotherapy [54]. 
Patients had to have received two cycles of cisplatin-based chemotherapy and a 
response or stable disease. The randomisation was performed 1 to 42 days after the 
end of radiotherapy. Few data are available regarding the initial chemoradiotherapy. 
Durvalumab was administered every 2 weeks for up to 12 months. The three year 
OS was 66.3% versus 43.5% for the placebo arm, results highly statistically signifi-
cant. The PD-L1 status was not known for all patients but a post hoc analysis found 
similar results regardless of PD-L1 status. The lung toxicity was 13% after dur-
valumab and 8% in the placebo arm but grade 3 pneumonitis rates were very similar 
(3.4% vs. 2.6%). It is also not easy to compare the observed survival to others series 
as randomisation in PACIFIC is done after initial chemoradiotherapy, excluding 
those patients progressing or not tolerating the initial treatment. Nevertheless, this 
trial has changed our daily practice by adding durvalumab quickly after the end of 
chemoradiotherapy in locally advanced NSCLC.
The question of finding the best combination of immunotherapy and radio-
therapy remains. Experimental data suggest better results when the drug is given 
during radiotherapy rather after its end: this was seen in an experimental study 
conducted on mice with colon carcinoma CT26 tumours [52]. One concern is the 
risk of increased toxicity especially at the level of lungs and heart: pneumonia is a 
classical complication of anti-PD-L1 drugs but also after chest radiotherapy. The 
NICOLAS phase II trial was designed specifically to answer this question [55]. 
Patients were treated with three cycles of a cisplatin-based chemotherapy and 
radiotherapy started with the second cycle together with nivolumab given up to 
1 year. The endpoint was grade 3 or more pneumonitis observed during 6 months 
after the end of RT. Amongst the 80 patients included, 8 developed grade 3 pneu-
monitis after radiotherapy.
Radiation may also release tumoral antigens allowing a better recognition by the 
immune system but also acting against tumour cells outside the radiation field (the 
so called “abscopal effect”). In the Pembroluzimab-RT phase II trial, patients with 
stage IV NSCLC were randomised between pembroluzimab alone and pembroluz-
imab given after SBRT to a single metastatic site [56]. The goal was to test if SBRT 
increases the response rate: 17 patients out of 36 presented a response with the 
combined approach vs. 9 out of 40 patients in the pembroluzimab alone arm. The 
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disease control rates at 12 weeks were respectively 63% vs. 40%. A retrospective 
study included 117 patients: 54 received SBRT with concurrent immune checkpoint 
inhibition and 63 SBRT alone. The risk of grade 3 radiation pneumonitis was higher 
in the combined approach (10.7% vs. 0%) [57]. In patients with a oligometastatic 
disease, the addition of a local treatment such as SBRT is a very exciting approach 
but a close monitoring for pneumonitis should be considered. Several trials are 
currently on-going.
Ultimately, there are a lot of unresolved questions: what is the optimal dose 
(low or high as the one used with SBRT), the actual volume to be treated, the 
timing…? Clearly, it is not easy to use a SBRT approach in stage III NSCLC as it is 
done for smaller metastatic lesions in stage IV NSCLC; the total volume to irradiate 
in stage III disease is much larger and could potentially lead to an excessive toxicity. 
Another issue lies in the volume of circulating immune cells during RT: the current 
technique to irradiate stage III NSCLC uses IMRT techniques delivering very low 
doses spread across large normal tissue volumes which may decrease the lympho-
cytes counts (a very sensitive cell to low RT dose), and subsequently the immune 
response. A retrospective study has observed a lower survival in case of lower 
absolute lymphocyte blood count [58]. So, blood-containing organs such as great 
vessels, heart and bone marrow may become a new organ at risk to spare in the 
future. Ideally, there is an urgent need to find a biomarker allowing to better select 
patients candidate for a combined approach in order to avoid futile treatments and 
also to decrease the expenses of those new treatments.
4. Small cell lung cancer (SCLC)
SCLC accounts for around 15% of all diagnosed lung cancers worldwide [59]. It 
is a highly aggressive, undifferentiated neoplasia characterised by a high prolifera-
tion rate and early metastatic spread. Although SCLC is very responsive to initial 
chemotherapy and radiotherapy, early recurrences are common and the prognosis 
of SCLC remains poor with 5-year overall survival rates of under 10% [60].
In the late 60’s, SCLC was staged as limited disease to the thorax (LS) or exten-
sive stage (ES) according to the Veterans’ Affairs Lung Study Group classification 
and later modified by the International Association for the Study of Lung (IASLC) 
[61, 62]. Interestingly, limited disease include tumour confined to the ipsilateral 
hemithorax and regional lymph nodes in order to be encompassed in a radiation 
field. More recently, the IASLC recommends to use the revised TNM staging clas-
sification for lung cancer (American Joint Committee on Cancer AJCC 7th edition) 
for clinical decision making and clinical trials instead of the LS- and ES-categories, 
as it better discriminate the prognostic impact [63, 64].
4.1 Limited stage-small cell lung cancer (LS-SCLC)
CRT is the current standard of care [65]. In the early 90’s two meta-analyses 
have outlined the benefit of adding chest RT to chemotherapy [66, 67]. The Pignon 
meta-analysis was the most interesting due to the utilisation of the patient indi-
vidual data from 13 randomised trials: chest RT improved the OS by 5.4% at 3 years 
but at the price of more esophagitis [67]. The benefit was greater for patients under 
55 years (the relative risk of death was 0.72), than for those over 70 years. Two 
meta-analyses of randomised controlled trials have looked to the timing of che-
motherapy and RT: concurrent CRT should start as early as the 1st or 2nd cycle of 
platinum-based chemotherapy to be more effective in terms of survival, compared 
to delaying the start of RT to the 3rd cycle or later [68, 69].
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Another question was the optimal dose and fractionation. In the Intergroup 
0096 trial, 471 patients were randomised between 45 Gy in 30 fractions twice 
daily (BiD), in a total of 3 weeks and 45 Gy in 25 fractions, once a day in 5 weeks. 
In both arm, RT started with the first of the 4 cycles of chemotherapy (cisplatin 
and etoposide) [70]. Overall survival rates at 2 and 5 years were respectively 41 
vs. 47%, and 16 vs. 26% (p = 0.04) in favour of the BiD treatment. The drawback 
was more acute toxicity, mainly grade 3–4 esophagitis, from 16–32% with the 
BiD but without any increase in the risk of grade 3 or higher pneumonitis (6% 
in both arms). Given the highly proliferative nature of SCLC, a shorter time 
between RT fractions and a shorter overall treatment time (3 weeks instead of 5) 
could explain the better results of BiD fractionation against tumour repopulation. 
However, the major limitation in the design of the Turrisi trial is that the two 
arms have not the same biologically equivalent dose, a higher dose for the BiD 
arm. Nevertheless, this pivotal trial confirmed the impact of a better local turn-
ing in a benefit of survival and cure. However, many radiation oncology centres 
did not use the BiD fractionation because of the increased oesophageal toxicity 
and the inconvenience for the patient linked to have two treatments on the same 
day with an interval of minimum 6 h between the 2 fractions but also for busy 
radiation facilities [71].
The Japan Clinical Oncology group JCO 9104 phase III trial compared a concur-
rent CRT to a sequential CRT and included 231 patients. Chest RT was delivered 
with the first of the 4 cycles of chemotherapy (cisplatine and etoposide) or one 
month after the last cycle. The chest RT was a BiD delivering 45 Gy in 30 fractions 
over 3 weeks [72]. The median OS was significantly better for the concurrent arm 
compared to the sequential one (27.2 vs. 19.7 months, p = 0.02 after adjustment 
for performance status, age, and stage in a Cox model). The oesophageal toxicity 
was quite similar between the two arms (4% vs. 9% for sequential vs. concurrent, 
respectively) but the haematological toxicity was increased with the concurrent 
treatment (grade 3–4 leukopenia: 88% vs. 54%, p < 0.001).
The CONVERT trial designed to answer the question rose by the Turrisi trial 
and included 547 patients [73]. The trial compared a BiD approach (45 Gy delivered 
in 30 fractions over 3 weeks) to an escalated daily RT (66 Gy in 33 fractions over 
6.5 weeks). The study was designed to show superiority for the once daily experi-
mental arm over the control BiD arm. While there was no difference in toxicity 
and OS between the two groups, the BiD arm showed a trend toward an improved 
median OS (30 vs. 25 months, p = 0.14), leading to the conclusion that BiD remains 
the standard of care. Still, a lot of radiotherapy centres prefer to use the more 
convenient once daily fractionation (at the total dose of 66 Gy) since survival and 
toxicity were similar in both arms [74]. A recent Scandinavian randomised phase 
II trial presented at the annual ASCO meeting randomised between high-dose BiD 
CRT of 60 Gy in 40 fractions (4 weeks) vs. 45 Gy in 30 fractions (3 weeks), both 
arms with 4 courses of platinum. The survival rate at 2 years were in favour of the 
60 Gy arm (73% vs. 46%, p = 0.001), and they had a significantly longer median OS 
(42 months vs. 23 months; HR 0.63, p = 0.031) without any significant differences 
in term of toxicity (esophagitis or grade 3–4 pneumonitis) [75]. Those promising 
results need a confirmation through a phase III trial including more than the 160 
patients. The RTOG is conducting a three arm trial comparing 70 Gy in 7 weeks, 
61.2 Gy delivered with one fraction daily of 1.8 Gy for 16 days followed by 1.8 Gy 
BiD for 9 days to the classical 45 Gy in 3 weeks BiD (RTOG 0538 trial); the second 
arm was prematurely closed.
Durvalumab has also showed activity for extensive SCLC and is tested as 
adjuvant treatment for limited disease with or without tremalimumab (The 
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Adriatic trial). In a phase III trial, Atezolumab is delivered concurrently with 
chest RT and cisplatine-etoposide(NRG-LU005). The results of the Stimuli 
trial were presented at the last ESMO congress. After the end of chemoradio-
therapy including also PCI, patients were randomised to receive ipilinumab and 
nivolumab for 12 months. No difference was observed in PFS neither in OS but 
increase the toxicity [76].
There is also the question of the target volume for radiotherapy: an elective nodal 
irradiation including the full mediastinum to treat the possible microscopic nodal 
sites was typically used in the past but at the cost of increased toxicity, an era of no 
PET-CT. In several prospective studies, the RT volume was limited to the known mac-
roscopic disease as seen on a PET-CT and failures outside were a rare event: 3% and 
2% in two different series of 60 patients from the Netherlands and the USA [77, 78].
Currently, the indications for surgery are limited to the very limited disease 
mainly stage I and II disease for fit patients and adjuvant chemotherapy is then 
necessary.
4.2 Extensive stage-small cell lung cancer (ES-SCLC)
The treatment cornerstone is a platinum-based chemotherapy regimens includ-
ing cisplatin or carboplatin and etoposide combined with immunotherapy. This 
first line treatment yields often excellent initial responses and improved survival. 
However, recurrent or persistent intrathoracic disease is observed in more than 75% 
patients and local control remains a major problem during the first year of follow-
up. A phase III study compared chest radiotherapy (54 Gy in 38 fractions over 
18 days with concurrent cisplatin/etoposide) to only additional cycles of chemo-
therapy [79]. Patients had to have obtained a complete response at the metastatic 
sites and a complete or partial response in the thorax. The combined approach led 
to a better survival: median survival time of 17 months vs. 11 months and a 5-year 
survival rate of 9.1% vs. 3.7%.
The CREST trial randomised 498 patients to evaluate the benefit in term of 
OS by adding chest RT (30 Gy in 10 fractions over 2 weeks) as a local consolida-
tion after first line cisplatin-based chemotherapy [80]. Although the study failed 
to achieve its initial endpoint of survival at 1-year, an interesting observation is 
certainly the slight survival improvement seen at 2 years: 13% vs. 3%, (p = 0.004). 
Importantly, RT allowed a marked 50% reduction in loco-regional recurrences. The 
radiation target volumes included the post-chemotherapy tumour and the nodal 
stations initially involved before the start of first line chemotherapy. These results 
lead to consider consolidative chest RT as a standard treatment after a response to 
chemotherapy, in addition to prophylactic cranial radiotherapy. Nevertheless, this 
is now questionable: two trials have showed a survival improvement by adding 
atezolumab to a platinum doublet [81, 82]. A trial is now on-going to evaluate the 
role of consolidative radiotherapy to up to 5 sites after a partial response or stable 
disease after a doublet of cisplatinum with atezolumab (Raptor trial).
4.3 Prophylactic cranial irradiation (PCI)
Brain metastases (BM) represent a major challenge in the management of SCLC, 
with an incidence as high as 50% at 2 years. The brain is considered a sanctuary site 
due to the blood brain barrier and the limited access for most available drugs. Based 
on prior experiences in leukaemia, Heine Hansen introduced in 1973 the concept of 
PCI for SCLC [83]. The aim of PCI is to prevent BM, avoiding the potential neuro-
logical complications, and ultimately to improve survival.
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Several randomised trials demonstrated that PCI decreased the incidence of BM 
and Auperin’s meta-analysis using the individual data of 987 SCLC patients from 
7 randomised trials confirmed clearly the survival benefits (both OS survival and 
PFS): PCI reduced by 25% the incidence of BM and increased the survival by 5,4% at 
3 years (20,7% vs. 15,3%) [84–86]. Most patients had a limited-stage disease (85%) 
considered in complete response to the initial chemotherapy. A more recent meta-
analysis including 1983 patients from 16 randomised trials showed a similar survival 
benefit without any impact of disease extent [87]. One problem with many trials is 
the lack of brain imaging in the initial staging and the CR evaluation: BM incidence 
is reduced by PCI from 53–40% in the absence of brain imaging while it reduces BM 
from 33 to 10% in case of brain CT-scan [88]. Today, MRI has increased the detec-
tion rate of BM from 10 to 24%. Importantly, the patients detected with BM by CT 
scan were often symptomatic while they had no symptoms in case of brain MRI.
The optimal radiation dose for PCI was tested by the large Intergroup PCI99–01 
trial: 720 patients were randomised between 25 Gy in 10 fractions in 2 weeks vs. 
36 Gy in 18 daily fractions or 24 BiD fractions [89]. This study failed to show any 
benefit with a higher radiation dose, neither on the incidence of BM or in survival; 
furthermore, the incidence of brain metastases remained high (35% at 3 years). 
Therefore, the recommended radiation schedule for PCI remains 25 Gy in 10 frac-
tions delivered in 2 weeks.
Toxicity remains a major concern: acute (hair loss, fatigue,..) or late (hearing 
and cognitive impairment, dementia, leukoencephalopathy,…). The cognitive func-
tions were evaluated before, at 6 and 12 months after PCI with the self-reported 
cognitive functions tests of EORTC: a threefold cognitive decline was observed at 
6 months as well as at 12 months after PCI [90]. Those neurocognitive functions are 
highly depending on the hippocampus area. Currently trials are on-going to evalu-
ate the efficacy and safety of a PCI using a hippocampus avoidance technique. Most 
guidelines recommend PCI for patients in complete response but it is also challenge 
by a close brain MRI follow-up [91, 92].
For patients presenting an extensive disease, PCI is also proposed after a 
response to platinum-based chemotherapy. This is based on the results of the 
EORTC phase III trial: patients with any response to chemotherapy were ran-
domised between PCI and no PCI. PCI reduced the incidence of BM from 40–16% 
at one year, leading to a significant survival increase (13–27%) [93]. A pooled 
analysis of the North Central Cancer Treatment Group (NCCTG) trials including 
421 patients observed similar results [94].
In contrast, a recent Japanese phase III trial randomised patients between PCI 
(25 Gy in 10 fractions) or no PCI after any response to initial chemotherapy and a 
recent MRI showing no BM [95]. The observation arm required to have brain MRI 
at 3-month intervals up to 12 months and at 18 and 24 months after enrolment. 
PCI reduced the incidence of BM but without any overall survival benefit: median 
survival was 11.6 months in the PCI group and 13.7 months in the observation group 
(HR = 1.27, 95% CI = 0.96–1.68; p = 0.094). Consequently, the Japan Lung Cancer 
Society removed PCI from their treatment guidelines in ES-SCLC. In those two trials, 
the patient population is quite different just by looking to the difference in survival. 
This trial and the concerns on PCI toxicity have led the SWOG to launch a trial com-
paring PCI to a MRI surveillance for extensive but also limited small cell lung cancer.
5. Conclusion
Over the past few years, major improvements have been made in the manage-
ment of lung cancer due to the introduction of SBRT and immunotherapy. Both 
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have changed the daily practice not only of early stage lung cancer but also for stage 
IV diseases. A major development in the future will be to include (SB) RT in the 
management of metastatic lung cancer to promote the immune system but also to 
treat local lung tumours. So, there is still a long way to understand how to optimise 
those modalities for each individual patient but also to understand the disease.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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